22 May 2013
Keywords: atherogenics, starts, ph, ii, ra, trial, agix-4207
Article | 27 October 2003
Atherogenics of the USA has commenced a Phase II trial of itsAGIX-4207 in patients with rheumatoid arthritis. The study, designated
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
27 October 2003
3 November 2003
© 2013 thepharmaletter.com